Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) announced that CEO Brian Markison and COO James Schaub will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) announced that CEO Brian Markison and COO James Schaub will present at the H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021. The presentation will be available on demand and archived for 30 days on the Company’s website. Osmotica focuses on developing specialty products for underserved markets, with subsidiaries including RVL Pharmaceuticals for ophthalmic products. The Company operates in the U.S. and Hungary.
Details
News Market Reaction – OSMT
The recorded move for OSMT in the trading session of this news was -0.72%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and James “JD” Schaub, Chief Operating Officer, will present at the H.C. Wainwright Ophthalmology Virtual Conference as follows:
| Date: | Tuesday, August 17, 2021 |
| Time: | On Demand |
| Webcast: | https://journey.ct.events/view/b4009ee7-d4bf-41a2-b263-30a028b27c98 |
The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.osmotica.com under the “Investor & News” section.
About Osmotica Pharmaceuticals plc
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting UPNEEQ®. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations.
Osmotica has operations in the United States and Hungary.
Investor and Media Relations for Osmotica Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.